The Seed Investor News Roundup - Big News For Canopy Growth

Read our Medical Marijuana Compound Report for Free Today!

The next big innovation is unfolding now and it’s already creating a wave of multi-millionaire investors in the process

Read the Investors Guide To Newly Emerging Marijuana Markets

LEARN MORE

Canopy deal seen as a potential ‘gamechanger’ for rallying pot stocks

Producers jump amid speculation alcohol companies will make further inroads into sector

Aurora Receives Cultivation License for Pointe-Claire, Quebec Site

Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company's 40,000 square foot, yield-optimized indoor production facility in Pointe-Claire, Quebec has received its cultivation license from Health Canada.

InMed’s eye-catching cannabinoid ‘lense’ for drug delivery

InMed Pharmaceuticals is developing a gel-based cannabinoid drug for eye diseases such as glaucoma, which it says could be cheaper and more accessible than cannabinoid-based products on the market.

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration

GW Pharmaceuticals completes the rolling submission of a new drug to the FDA for treatment of two forms of childhood-epilepsy.

Canopy Growth Establishes Groundbreaking Strategic Relationship With Constellation Brands

Canopy Growth Corporation (TSX: WEED) is proud to announce that it has agreed to enter into a strategic relationship with the leading total beverage alcohol supplier in the United States, Constellation Brands (NYSE: STZ and STZ.B).

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.

TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260

info@theseedinvestor.com

To keep receiving emails from us, please add us to your address book.